Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Inc.
This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male or nonpregnant, nonlactating females aged between 18 and 65 years (inclusive)
Body Mass Index (BMI) of 30-45 Kg/m\^2.
Non-smoker
No concomitant medications
No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency
